Tokyo Tape
Sign in
← Toho Holdings

Quarterly report · Q3

8129.TEDINET S100Q4UF
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
MetricValuePeriodScopeSource row
Revenue¥1.06T2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥1.27T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥950.2bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥8.6bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥5.5bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥13.4bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥18.2bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥9.9bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥14.4bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥10.4bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥9.5bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥6.9bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥9.6bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥6.9bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥794.4bnat 2022-12-31Cons.Assets
Total assets¥702.4bnat 2022-03-31Cons.Assets
Total assets¥731.5bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥554.0bnat 2022-12-31Cons.Liabilities
Total liabilities¥461.1bnat 2022-03-31Cons.Liabilities
Net assets / equity¥240.4bnat 2022-12-31Cons.Net assets
Net assets / equity¥241.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥238.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥112.9bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥94.3bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥136.092022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥85.92022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥189.72021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥97.982021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥51.582021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥125.12022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥174.482021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥90.072021-04-01 → 2021-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio30.2%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio34.3%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.5%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥43.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥43.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥1.1bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue2022-04-01 → 2022-12-31¥68.8bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2022-04-01 → 2022-12-31¥68.8bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥4m
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.7bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2022-04-01 → 2022-12-31¥7.4bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.6bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5.8bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2022-04-01 → 2022-12-31¥715m
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue2022-04-01 → 2022-12-31¥1.02T
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue external2022-04-01 → 2022-12-31¥983.6bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥36.4bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.8bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥4.9bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥3.8bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥1.2bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥449m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥1.10T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥1.06T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥43.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥9.7bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥43.3bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥43.3bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥1.4bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue2021-04-01 → 2021-12-31¥68.9bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2021-04-01 → 2021-12-31¥68.9bn
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥5m
jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2021-04-01 → 2021-12-31¥2.3bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2021-04-01 → 2021-12-31¥6.7bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2021-04-01 → 2021-12-31¥1.4bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥5.3bn
jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2021-04-01 → 2021-12-31¥691m
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue2021-04-01 → 2021-12-31¥913.8bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue external2021-04-01 → 2021-12-31¥876.8bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥37.0bn
jpcrp040300-q3r_E02608-000Medical Products Retailreportable segmentsegment profit2021-04-01 → 2021-12-31¥3.6bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥4.2bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥3.1bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥1.0bn
jpcrp040300-q3r_E02608-000Other Related Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥308m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥993.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥950.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥43.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥6.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 418
ItemContextValueUnit
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration-24000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration58000000JPY
Other comprehensive incomePrior1YTDDuration-4129000000JPY
Other comprehensive incomeCurrentYTDDuration-634000000JPY
Comprehensive incomePrior1YTDDuration2806000000JPY
Comprehensive incomeCurrentYTDDuration8917000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration2780000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration8899000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration26000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration17000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsRetailReportableSegmentsMember876813000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E02608-000DispensingPharmacyReportableSegmentsMember68904000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember1377000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E02608-000OtherRelatedBusinessReportableSegmentMember3124000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember950219000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration950219000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsRetailReportableSegmentsMember36976000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E02608-000DispensingPharmacyReportableSegmentsMember5000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember5326000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E02608-000OtherRelatedBusinessReportableSegmentMember1029000000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember43338000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-43338000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsRetailReportableSegmentsMember913790000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E02608-000DispensingPharmacyReportableSegmentsMember68910000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember6703000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E02608-000OtherRelatedBusinessReportableSegmentMember4154000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember993557000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-43338000000JPY
Net salesPrior1YTDDuration950219000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsRetailReportableSegmentsMember3648000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E02608-000DispensingPharmacyReportableSegmentsMember2280000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember691000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E02608-000OtherRelatedBusinessReportableSegmentMember308000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember6928000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-1378000000JPY
Operating incomePrior1YTDDuration5549000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsRetailReportableSegmentsMember983583000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E02608-000DispensingPharmacyReportableSegmentsMember68839000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember1613000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E02608-000OtherRelatedBusinessReportableSegmentMember3777000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember1057814000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration1057814000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsRetailReportableSegmentsMember36401000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E02608-000DispensingPharmacyReportableSegmentsMember4000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember5829000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E02608-000OtherRelatedBusinessReportableSegmentMember1161000000JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember43396000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass